OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)

Article	Citations
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	883
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	862
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	847
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	829
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	779
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	580
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	429
Recent advances in targeting protein degradation for tumor immunotherapy	412
Cytokines and cancer-associated fibroblasts	380
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	358
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	338
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	338
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	332
Cancer vaccines: current status and future directions	318
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	316
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	306
Landscape of biallelic DNMT3A mutant myeloid neoplasms	294
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	292
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	290
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	272
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	249
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	238
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	235
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	234
Personalized nanovaccines for treating solid cancer metastases	232

HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	229
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	226
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	209
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	209
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	209
Recent advances in therapeutic strategies for non-small cell lung cancer	206
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	204
Ferroptosis: principles and significance in health and disease	197
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	195
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	195
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	194
Multiple myeloma risk linked to DNA damage response genes	188
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	186
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	186
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies	185
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	176
Recent advances in targeted strategies for triple-negative breast cancer	175
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	173
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	172
Small RNA modifications: regulatory molecules and potential applications	169
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	168
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	166
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	163
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	160
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	158
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	157
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	155
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	152
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	150
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	150
A single-cell and spatially resolved atlas of human osteosarcomas	148
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	145
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	143
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	142
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	141
Target neutrophil heterogeneity and plasticity in cancer	138
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	136
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	133
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	133
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	132
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	131
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	130
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	130
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	129
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	128
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	127
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	124
The functional and clinical roles of liquid biopsy in patient-derived models	122
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	121
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	120

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	118
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	113
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	113
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	108
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	106
Challenges and new technologies in adoptive cell therapy	104
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	103
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	102
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	101
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	100
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	98
Gastric cancer treatment: recent progress and future perspectives	98
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	96
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	96
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	96
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality	95
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy	95
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	93
Targeting GPRC5D for multiple myeloma therapy	89
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	88
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	87
Metabolic reprogramming in the tumor microenvironment of liver cancer	85
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	83
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	83
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	82
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	81
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	81
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	78
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	76
Correction: Immunosenescence: a key player in cancer development	75
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	75
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	75
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	74
Advances in targeting histone deacetylase for treatment of solid tumors	73
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	73
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	72
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	72
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	72
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	71
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	71
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	70
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	69
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	69
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	68
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	66
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	66
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	65
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	63
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	62
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	60
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	60
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer	60
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	59
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	58
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies	58
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	55
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	55